fbpx
Menu

MEDIFIRST SOLUTIONS ANNOUNCES NEW AGREEMENT FOR CBD PRODUCTS AND DISTRIBUTION

Share

MEDIFIRST SOLUTIONS, INC. (OTC: MFST) (the Company or Medifirst), a provider of innovative laser technology with its FDA 510(k) cleared Infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device and a provider of Specialty Pharmacy Drug Consulting Services is pleased to announce an update regarding its new cannabidiol (CBD) division. 

Medifirst is pleased to announce that it has launched a majority-owned subsidiary USA Pharma, Inc., a division for its CBD distribution, sales and products. Medifirst is also pleased to announce it has completed an agreement with Dr. Gupta Pharma LLC to distribute a line of premium CBD oils. Dr. Sanjay Gupta, its Chief Executive Officer, not related to Dr. Gupta of CNN, is a physician who specializes in the treatment of pain, and is the President of the American Pain Association. Dr. Gupta has created his own line of CBD products that, Medifirst believes, is superior in quality and production process to any CBD product in the industry. Today, Medifirst President Bruce J. Schoengood, stated that We believe that the CBD products in Dr. Guptas product line will have great interest and demand by physicians and the medical community, in addition to producing unrivaled quality products for consumers. The company plans to release further detail regarding this agreement within days of this announcement. There is already a great demand for all natural and drug free products for relieving pain, anxiety, stress and many other ailments and conditions. CBD is widely believed to have great medicinal value and potential. About The Time Machine Laser Medifirst Solutions, Inc., in response to its Premarket Notification 510(k) submission for The Time Machine Series Laser, received clearance from the U.S. Food and Drug Administration (FDA) to market its infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device. The Time Machine Series Lasers Model TTML-8102000 – …

[Read on via official release]

Source: US SEC
View full document:
8-K_for_Medifirst_Solutions_Inc_8-K-11-21-2018